Patents by Inventor Lorin K. Johnson

Lorin K. Johnson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220175764
    Abstract: The present disclosure is directed to the use of methylnaltrexone, or a salt thereof, and rifaximin for the treatment of increased gut permeability, or an associated disorder, e.g., NASH or NAFLD.
    Type: Application
    Filed: November 18, 2021
    Publication date: June 9, 2022
    Applicant: Bausch Health Ireland Limited
    Inventors: Lorin K. Johnson, XiaoJun Nicole Deng, William J. Jo Siu, Robert J. Israel, Zeev Heimanson
  • Publication number: 20210121456
    Abstract: Presented herein are methods for preventing or treating tumor growth, tumor metastasis and/or abnormal proliferation of tumor cells in a subject, wherein the methods involve administration of a pharmaceutical composition comprising methylnaltrexone. Also presented herein are methods for inhibiting or slowing the growth of a tumor in a subject, wherein the methods include selecting a subject who is a suitable candidate for treatment with methylnaltrexone, and administering a composition comprising methylnaltrexone to the subject.
    Type: Application
    Filed: October 5, 2020
    Publication date: April 29, 2021
    Applicants: Salix Pharmaceuticals, Inc., The University Of Chicago
    Inventors: Jonathan Moss, Lorin K. Johnson
  • Publication number: 20200163958
    Abstract: Presented herein are methods for preventing or treating tumor growth, tumor metastasis and/or abnormal proliferation of tumor cells in a subject, wherein the methods involve administration of a pharmaceutical composition comprising methylnaltrexone. Also presented herein are methods for inhibiting or slowing the growth of a tumor in a subject, wherein the methods include selecting a subject who is a suitable candidate for treatment with methylnaltrexone, and administering a composition comprising methylnaltrexone to the subject.
    Type: Application
    Filed: October 29, 2019
    Publication date: May 28, 2020
    Applicants: Salix Pharmaceuticals, Inc., The University Of Chicago
    Inventors: Jonathan Moss, Lorin K. Johnson
  • Publication number: 20170202832
    Abstract: Presented herein are methods for preventing or treating tumor growth, tumor metastasis and/or abnormal proliferation of tumor cells in a subject, wherein the methods involve administration of a pharmaceutical composition comprising methylnaltrexone. Also presented herein are methods for inhibiting or slowing the growth of a tumor in a subject, wherein the methods include selecting a subject who is a suitable candidate for treatment with methylnaltrexone, and administering a composition comprising methylnaltrexone to the subject.
    Type: Application
    Filed: April 3, 2017
    Publication date: July 20, 2017
    Applicants: Salix Pharmaceuticals, Inc., The University of Chicago
    Inventors: Jonathan Moss, Lorin K. Johnson
  • Publication number: 20160279153
    Abstract: The invention relates to formulations and dosage schedules of balsalazide. The invention further relates to methods of producing pharmaceutical formulations of balsalazide.
    Type: Application
    Filed: February 1, 2016
    Publication date: September 29, 2016
    Applicant: Salix Pharmaceuticals, Inc.
    Inventors: Joseph Lockhart, Brock Swanson, Lorin K. Johnson
  • Publication number: 20160000765
    Abstract: The present invention provides new methods of treating bowel disease (BD) by increasing a durability of response; treating BD in males; treating BD in adolescent subjects; treating bloating due to BD in males; and methods of maintaining remission of BD.
    Type: Application
    Filed: July 14, 2015
    Publication date: January 7, 2016
    Inventors: William Forbes, Lorin K. Johnson
  • Publication number: 20150132381
    Abstract: The instant application provides methods and compositions for the treatment of male subjects having ulcerative colitis.
    Type: Application
    Filed: October 8, 2014
    Publication date: May 14, 2015
    Applicant: SALIX PHARMACEUTICALS, LTD
    Inventors: William Forbes, Enoch Bortey, Lorin K. Johnson
  • Publication number: 20130295178
    Abstract: The instant application provides methods and compositions for the treatment of male subjects having ulcerative colitis.
    Type: Application
    Filed: July 10, 2013
    Publication date: November 7, 2013
    Inventors: William Forbes, Enoch Bortey, Lorin K. Johnson
  • Publication number: 20070167416
    Abstract: A method of increasing the bioavailability of 5-aminosalicylate compound by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of 5-aminosalicylate compound in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food.
    Type: Application
    Filed: November 3, 2006
    Publication date: July 19, 2007
    Inventor: Lorin K. Johnson
  • Patent number: 5905073
    Abstract: The present invention provides a method of colon cancer chemoprevention or chemotherapy comprising administering to an individual suffering from colon cancer or at risk to develop colon cancer a pharmaceutical composition comprising an effective amount of a 2-hydroxy-5-phenylazobenzoic acid derivative or an ester of an active metabolite or an oxidation product of an active metabolite thereof, or a pharmacologically acceptable salt of the 2-hydroxy-5-phenylazobenzoic acid derivative or an ester or an active metabolite or an oxidation product of an active matabolite thereof.
    Type: Grant
    Filed: July 11, 1996
    Date of Patent: May 18, 1999
    Assignee: Salix Pharmaceuticals, Inc.
    Inventors: Lorin K. Johnson, Marvin H. Sleisenger
  • Patent number: 5646254
    Abstract: Antibodies which react with the human phospholipase inhibitory protein/apolipoprotein AIV complex and hPIP are provided.
    Type: Grant
    Filed: April 26, 1994
    Date of Patent: July 8, 1997
    Assignee: Scios Nova Inc.
    Inventors: Lorin K. Johnson, John P. Longenecker
  • Patent number: 5552530
    Abstract: Antibodies that specifically bind to and inhibit the enzymatic activity of synovial phospholipase A.sub.2 Type A are described. The antibodies may be used in assays for detection of synovial phospholipase A.sub.2 in biological samples.
    Type: Grant
    Filed: August 1, 1994
    Date of Patent: September 3, 1996
    Assignee: Eli Lilly & Company
    Inventors: Lorin K. Johnson, Jeffrey J. Seilhamer, Waldemar Pruzanski, Peter Vadas
  • Patent number: 5498608
    Abstract: The present invention provides a method of colon cancer chemoprevention or chemotherapy comprising administering to an individual suffering from colon cancer or at risk to develop colon cancer a pharmaceutical composition comprising an effective amount of a 2-hydroxy-5-phenylazobenzoic acid derivative or an ester of an active metabolite thereof, or a pharmacologically acceptable salt of the 2-hydroxy-5-phenylazobenzoic acid derivative or an ester or an active metabolite thereof.
    Type: Grant
    Filed: January 7, 1994
    Date of Patent: March 12, 1996
    Assignee: Salix Pharmaceuticals
    Inventors: Lorin K. Johnson, Marvin H. Sleisenger
  • Patent number: 5342764
    Abstract: Cloning and expression of the gene encoding human phospholipase inhibitory protein (hPIP) permits production of an anti-inflammatory protein in practical quantities using recombinant techniques.
    Type: Grant
    Filed: September 1, 1993
    Date of Patent: August 30, 1994
    Assignee: Scios Nova Inc.
    Inventors: Lorin K. Johnson, John P. Longenecker
  • Patent number: 5264550
    Abstract: Cloning and expression of the gene encoding human phosphlipase inhibitory protein (hPIP) permits production of an anti-inflammatory protein in practical quantities using recombinant techniques.
    Type: Grant
    Filed: April 20, 1992
    Date of Patent: November 23, 1993
    Assignee: Scios Nova Inc.
    Inventors: Lorin K. Johnson, John P. Longenecker
  • Patent number: 5047397
    Abstract: Compounds and compositions comprising synthetic analogs of Atrial Natriuretic Peptides are provided, together with methods for their production and use as natriuretics, diuretics and/or vasodilators, or as intermediates for or modulators of such useful compounds or of native Atrial Natriuretic Peptides.
    Type: Grant
    Filed: December 16, 1988
    Date of Patent: September 10, 1991
    Assignee: California Biotechnology Inc.
    Inventors: Robert M. Scarborough, John A. Lewicki, Lorin K. Johnson
  • Patent number: 5019508
    Abstract: Mammalian synovial phospholipase A.sub.2 (sPLA.sub.2) enzymes are provided, as well as DNA constructs encoding these enzymes, methods of producing the enzymes recombinantly, and antibodies thereto. Therapeutic methods employing anti-synovial phospholipase antibodies are also provided, in addition to diagnositc methods and other applications of sPLA.sub.2.
    Type: Grant
    Filed: July 6, 1988
    Date of Patent: May 28, 1991
    Assignees: Biotechnology Research Partners, Ltd., The University of Toronto Innovations Foundation
    Inventors: Lorin K. Johnson, Jeffrey J. Seilhamer, Waldemar Pruzanski, Peter Vadas
  • Patent number: 4935492
    Abstract: Compounds and compositions comprising cyclic synthetic analogs of Atrial Natriuretic Peptides are provided, together with methods for their production and use as natriuretics, diuretics and/or vasodilators, or as intermediates for or modulators of such useful compounds or of native Atrial Natriuretic Peptides.
    Type: Grant
    Filed: March 29, 1988
    Date of Patent: June 19, 1990
    Assignee: California Biotechnology Inc.
    Inventors: John A. Lewicki, Robert M. Scarborough, Lorin K. Johnson
  • Patent number: 4804650
    Abstract: Compounds and compositions comprising synthetic analogs of Atrial Natriuretic Peptides are provided, together with methods for their production and use as natriuretics, diuretics and/or vasodilators, or as intermediates for or modulators of such useful compounds or of native Atrial Natriuretic Peptides.
    Type: Grant
    Filed: March 16, 1988
    Date of Patent: February 14, 1989
    Assignee: Biotechnology Research Associates, J.V.
    Inventors: John A. Lewicki, Robert M. Scarborough, Jr., Lorin K. Johnson
  • Patent number: 4764504
    Abstract: Methods and compositions are provided for inducing natriuresis, diuresis and vasodilatation in mammalian hosts by administering atrial natriuretic/vasodilator polypeptides to said host. Also provided are methods for producing such polypeptides, and antibodies which are capable of recognizing and specifically binding to them.
    Type: Grant
    Filed: May 8, 1985
    Date of Patent: August 16, 1988
    Assignee: Biotechnology Research Associates J.V.
    Inventors: Lorin K. Johnson, Steven A. Atlas, Brian J. McCarthy, John H. Laragh, John A. Lewicki